

Quantitative production of macrophages or neutrophils *ex vivo* using conditional Hoxb8

Gang G Wang^{1,2}, Katherine R Calvo^{1,3}, Martina P Pasillas¹, David B Sykes^{1,4}, Hans Häcker⁵ & Mark P Kamps¹

Differentiation mechanisms and inflammatory functions of neutrophils and macrophages are usually studied by genetic and biochemical approaches that require costly breeding and time-consuming purification to obtain phagocytes for functional analysis. Because Hox oncoproteins enforce self-renewal of factor-dependent myeloid progenitors, we queried whether estrogen-regulated Hoxb8 (ER-Hoxb8) could immortalize macrophage or neutrophil progenitors that would execute normal differentiation and normal innate immune function upon ER-Hoxb8 inactivation. Here we describe methods to derive unlimited quantities of mouse macrophages or neutrophils by immortalizing their respective progenitors with ER-Hoxb8 using different cytokines to target expansion of different committed progenitors. ER-Hoxb8 neutrophils and macrophages are functionally superior to those produced by many other *ex vivo* differentiation models, have strong inflammatory responses and can be derived easily from embryonic day 13 (e13) fetal liver of mice exhibiting embryonic-lethal phenotypes. Using knockout or small interfering RNA (siRNA) technologies, this ER-Hoxb8 phagocyte maturation system represents a rapid analytical tool for studying macrophage and neutrophil biology.

Phagocytic cells and inflammation are important in immunologic regulation as well as in the pathology of chronic inflammatory diseases (for example, multiple sclerosis, liver cirrhosis, arthritis, atherosclerosis, diabetes, vascular diseases and inflammatory bowel disease) and acute inflammatory disease (for example, toxic shock syndrome). Normal inflammatory processes have also been linked to complex diseases such as the proliferation and metastasis of cancer¹ and the development of obesity². Understanding the molecular mechanisms by which a phagocyte responds to chemokines and cytokines, activates a proinflammatory cascade, modulates lymphocyte expansion and function, and effects microbial killing will ultimately reveal mechanisms of chronic inflammation, whereas identification of the genetic pathways that control phagocyte differentiation is important for understanding myeloid leukemogenesis. Although the function of innate immune proteins can be studied by knockout technologies that reveal their importance in

phagocyte functions, there is no simple protocol to generate large numbers of neutrophils or monocytes from these mutant mice to characterize the impact of a genetic mutation on their differentiation, signal transduction or effector functions.

Class I Hox home domain transcription factors promote the expansion of hemopoietic progenitors, and their expression is deregulated in both human and mouse myeloid leukemia. The abundance of Hoxa9 and Hoxa7 is high in CD34+, Sca-1+, lineage-negative (Lin⁻) bone marrow populations that are enriched in hematopoietic stem cells (HSC) and in lineage-committed progenitors, and both are downregulated coincident with transition to the CD34⁻ stage of early progenitor differentiation^{3,4}. *Hoxa9*^{-/-} mice have five- to tenfold fewer marrow HSC and substantial reductions in myeloid and pre-B cell progenitors⁴, whereas retroviral expression of Hoxa9 produces a tenfold increase in the number of long-term repopulating HSC (LT-HSC)⁵. Enforced production of Hoxb8 or Hoxa9 blocks differentiation of stem cell factor (SCF)- or granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent myeloid progenitors⁶⁻⁹.


Based on the ability of Hox proteins to arrest myeloid differentiation and permit infinite progenitor expansion, we asked whether factor-dependent hematopoietic progenitors immortalized by estrogen receptor fusions (conditional forms) of Hoxb8 or Hoxa9 could yield cell models of normal neutrophil- or macrophage-restricted differentiation. By testing combinations of progenitor isolation protocols, cytokines used for pre-stimulation and long-term culture, and oncoprotein identity, we developed a simple and reliable protocol to derive macrophage-committed progenitor lines and a second protocol to derive neutrophil-committed progenitor lines.

Based on immunologic, functional and genetic criteria, the macrophages and neutrophils produced from these lines model normal exit from the cell cycle, and acquisition of phagocytic and inflammatory functions. In response to Toll-receptor agonists, macrophages derived from ER-Hoxb8 progenitors upregulated components of NF- κ B signaling and downstream effector genes such as *Il1*, *Il6*, *Ptgs2* and *Tgm2*. The ability of ER-Hoxb8 to drive progenitor expansion and permit their subsequent differentiation

¹Department of Pathology & Molecular Pathology Graduate Program and ²Biomedical Sciences Graduate Program, School of Medicine, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA. ³Laboratory of Pathology, National Health Institutes, National Cancer Institute, 10 Center Drive, Bldg. 10, 2N212, Bethesda, Maryland 20892, USA. ⁴Department of Medicine, Harvard Massachusetts General Hospital, 55 Fruit Street, Boston Massachusetts 02114, USA. ⁵St. Jude Children's Research Hospital, Department of Infectious Diseases, Room E8062, 332 North Lauderdale Street, Memphis, Tennessee 38105, USA. Correspondence should be addressed to M.P.K. (mkamps@ucsd.edu).

Figure 1 | ER-Hoxb8 and ER-Hoxa9 function conditionally at the biochemical and cellular levels. **(a)** Estrogen-binding domain (ERBD) of the estrogen receptor fused to Hoxa9 or Hoxb8. Epitope tags, Flag and Glu-Glu (EE) are indicated on the left. HD represents the home domain. **(b)** Concentration-dependent transcriptional activity of ER-Hoxa9, measured as coactivation through TGAT-TTAT motifs in cooperation with E2a-Pbx1 in 293T cells. ER-Hoxb8 yielded a similar concentration-dependent activation curve. **(c)** Immobilization kinetics of GM-CSF-dependent progenitors after infection by ER-Hoxa9 or ER-Hoxb8 retrovirus in the presence of estrogen.

Retroviral infection was performed at day 0, and dashed lines signify duration of selection in G418. Inserted panel represents a western blot using anti-Hoxa9 (left) and anti-Flag (right) on G418-selected, immortalized progenitors. Immobilization kinetics and doubling times were somewhat faster for progenitors derived in SCF. **(d)** Proliferation of GM-CSF-dependent progenitors immortalized by ER-Hoxa9 or ER-Hoxb8 in continued presence or after withdrawal of estrogen (ES) on day 0.



to neutrophils or macrophages makes this model system an ideal tool to study myeloid differentiation as well as cell biology and inflammatory functions of macrophages and neutrophils.

RESULTS

ER-Hoxb8 and ER-Hoxa9 exhibit estrogen-stimulated function

We fused the estrogen-binding domain of the estrogen receptor (ER) to the N terminus of Hoxb8 and Hoxa9, added N-terminal epitope tags to facilitate subsequent identification, and expressed the fusion cDNAs using a murine stem cell virus (MSCV) retroviral expression vector (Fig. 1a). We measured estrogen-regulated transcriptional function of ER-Hoxb8 and ER-Hoxa9 by virtue of their ability to cooperate with activated forms of Pbx to activate transcription of a luciferase reporter driven by TGAT-TTAT Pbx-Hox motifs. Using this assay, ER-Hoxa9 and ER-Hoxb8 exhibited estrogen-dependent transcriptional activation of ten- and threefold, respectively, with half-maximal activation occurring at 10 nM estrogen (Fig. 1b).

ER-Hoxb8 immortalizes neutrophil or macrophage progenitors

In the presence of 1 μ M estrogen, infection of primary marrow progenitors cultured in interleukin 3 (IL-3), SCF or GM-CSF with retrovirus expressing genes encoding ER-Hoxb8 or ER-Hoxa9 produced immortalized factor-dependent progenitors (Fig. 1c), which ceased proliferation (Fig. 1d) and exhibited terminal morphologic differentiation upon estrogen withdrawal (Fig. 2a). Progenitors were not immortalized when infections were performed in the presence of granulocyte colony stimulating factor (G-CSF) or macrophage colony stimulating factor (M-CSF). By testing different progenitor isolation protocols, cell culture conditions and ER-Hox fusion oncoproteins, we determined conditions for derivation of cell lines demonstrating quantitative neutrophil differentiation or quantitative macrophage differentiation. By using negative selection (removing Mac1+, B220+, Thy1.2+ cells) of total bone marrow progenitors followed by a 2-d pre-expansion in SCF, IL-3 and IL-6, and immortalization with ER-Hoxb8 retrovirus in medium containing SCF as the only cytokine, immortalized




Figure 2 | SCF ER-Hoxb8 progenitors execute neutrophil differentiation and GM-CSF ER-Hoxb8 progenitors execute macrophage differentiation. **(a)** Morphological changes of SCF ER-Hoxb8 neutrophil progenitors (left six images) and GM-CSF ER-Hoxb8 macrophage progenitors (right six images) after 6 d of cell culture in the absence of estrogen. Identical magnifications were used within the context of the phase contrast, Wright-Giemsa and differentiation marker images. Scale bars, 30 μ m. **(b)** FACS analysis of neutrophil and macrophage surface markers present on ER-Hoxb8 progenitors in the presences of estrogen (blue) or after the removal of estrogen for 6 d (red). Analyzed are Gr-1 (neutrophil differentiation antigen), F4/80 (macrophage differentiation antigen) and Mac1 (general myeloid differentiation antigen).

progenitors differentiated into 98–99% neutrophils after estrogen withdrawal (1–2% mast cells with an occasional eosinophilic granulocyte; 4 of 4 clones; **Fig. 2a**). We named progenitors derived in this manner ‘SCF ER-Hoxb8 progenitors’. SCF ER-Hoxb8 progenitors have proliferated over 9 months, maintaining both a normal 40-XX karyotype (19 of 20 chromosome spreads) and quantitative neutrophil differentiation. By contrast, when we purified total marrow progenitors by centrifugation onto Ficoll (no negative selection for Mac1⁺ committed myeloid progenitors) and immortalized them with *ER-Hoxb8* retrovirus in medium containing GM-CSF as the only cytokine, the progenitors are committed to macrophage differentiation at levels >99% (**Fig. 2a**; 10 of 10 clones). We named progenitors derived in this manner ‘GM-CSF ER-Hoxb8 progenitors’. These progenitors have proliferated over two years (over 850 generations), maintaining a normal 40-XX karyotype (in 17 of 20 chromosome spreads; **Supplementary Fig. 1** online) and quantitative macrophage differentiation. Therefore, ER-Hoxb8 progenitors do not become aneuploid as a requirement for immortalization, they do not become aneuploid at a substantial rate over long durations of passage, and they maintain stable commitment to lineage-restricted differentiation pathways.

We characterized neutrophil or macrophage progenitors immortalized by ER-Hoxb8 for surface antigens and enzyme activities characteristic of neutrophils or macrophages. Neutrophils produced by differentiation of SCF ER-Hoxb8 progenitors upregulated NADPH oxidase (**Fig. 2a**), the neutrophil surface antigen Gr-1 and the myeloid integrin Mac1, and downregulated the macrophage marker F4/80 (**Fig. 2b**). By contrast, macrophages produced by differentiation of GM-CSF ER-Hoxb8 macrophage progenitors exhibited activation of macrophage-nonspecific esterase (**Fig. 2a**), upregulation of F4/80 and Mac1 and downregulation of Gr-1 (**Fig. 2b**).

Contrasting the behavior of ER-Hoxb8, ER-Hoxa9 and ER-Hoxa7 progenitors exhibited principally biphenotypic neutrophil and macrophage differentiation regardless of the cytokine used during their derivation. Among 23 clones of GM-CSF ER-Hoxa9 progenitors, 4 exhibited strict neutrophil differentiation, 1 exhibited exclusive macrophage differentiation and 18 exhibited biphenotypic differentiation that favored production of neutrophils over macrophages. We continued characterization of ER-immortalized progenitors because they did not require cloning to select progenitors that differentiated into pure populations of neutrophils or macrophages, and because a simple change in experimental protocol allowed for derivation of either macrophage- or neutrophil-committed progenitors.

Genomic arrays demonstrate normal specific differentiation

We interrogated Affymetrix genome arrays (430 2.0 Array; over 34,000 mouse genes) with RNA from SCF ER-Hoxb8 progenitors undergoing neutrophil differentiation and from GM-CSF ER-Hoxb8 progenitors undergoing macrophage differentiation (**Supplementary Tables 1–4** online) and compared expression of 130 macrophage-specific, neutrophil-specific or general myeloid genes (**Fig. 3**). *Il8rb*, *Ltf*, *Lrg1*, *CD177*, *Camp*, *Lcn2* and other neutrophil marker genes were upregulated selectively during differentiation of SCF ER-Hoxb8 neutrophil progenitors whereas *Mmp12*, *Cd68*, *Msr1*, *Msr2*, *Mgl2*, *Itgax* (CD11c), *Clec4n* and other macrophage-specific marker genes were upregulated selectively with differentiation of GM-CSF ER-Hoxb8 macrophage progenitors (**Supplementary Tables 1** and **2**). The monocytic lineage markers *Irf8*, *Emr1* (*F4/80*) and *Tfcp* (also known as *Tfcp*) were expressed at high levels in undifferentiated GM-CSF ER-Hoxb8 progenitors, demonstrating their commitment to




Figure 3 | Lineage-specific gene expression in SCF ER-Hoxb8 neutrophil progenitors and GM-CSF ER-Hoxb8 macrophage progenitors. (**a,b**) Affymetrix gene arrays were used to quantify the expression levels of 130 myeloid genes in a ER-Hoxb8 SCF neutrophil cell line (**a**) and a GM-CSF ER-Hoxb8 macrophage cell line (**b**) in the presence of estrogen (blue) and at 6 d of differentiation after estrogen withdrawal (red). Genes plotted are underlined with the categories in **Supplementary Table 3**. The y-axis plots the relative abundance of RNA, with blue designating basal levels in undifferentiated progenitors and red designating levels in differentiated cells after 6 d of estrogen withdrawal.




Figure 4 | SCF ER-Hoxb8 progenitors behave as GMP, retaining an ability to differentiate into eosinophils and macrophages. SCF ER-Hoxb8 progenitors were permitted to differentiate in SCF medium supplemented with the lineage-specific cytokines GCSF, IL5, MCSF and GM-CSF, as indicated above the images. Cells were photographed 6 d after differentiation was initiated by removal of estrogen. In the column labeled 'SCF+IL5', a developing eosinophil is magnified at lower left. All photographs within the "Visible" and "Wright-Giemsa" series are presented at identical magnifications. Proportions of mature cell types within cell cultures after 6 d of differentiation are indicated below each column. Scale bars, 30 μ m.

macrophage differentiation (**Supplementary Table 1**). Other common myeloid marker genes were upregulated during maturation of both progenitor cell types (*Fpr1*, *Fpr-rs2*, *Mrc1*, *Tlr2*, *Mmp8*, *Itgam*, *Fgr*, *Lgmn*), whereas common promyelocytic genes, including *Mpo*, *Prt3*, *Ela2* and *Cnn3* were strongly downregulated (**Supplementary Table 1**). Dynamic regulation of neutrophil, macrophage and general myeloid markers demonstrates that both the SCF and GM-CSF ER-Hoxb8 progenitors execute normal differentiation programs. We verified changes in gene expression predicted by Affymetrix arrays for the macrophage scavenger receptor (*Msr1*) and the transcription factors Rel-B and Jun using immunoblotting, for CD11c using fluorescence-activated cell sorting (FACS) analysis, and for *Gfi1*, *Myb*, *Nolc1*, *Ela2* and *Fos* by northern blotting (**Supplementary Fig. 2** online).

GM-CSF ER-Hoxb8 macrophage progenitors were positioned at a later stage of myeloid differentiation than were SCF ER-Hoxb8 neutrophil progenitors. They exhibited high basal levels of a subset of late differentiation genes, such as *Lyzs*, *Gsn*, *Cd14*, *Lilrb4*, *Pira1*, *Pira6*, *Pilrb*, *Gp49b1* and *Gpnmb* that were not expressed in SCF ER-Hoxb8 neutrophil progenitors, but were strongly upregulated SCF ER-Hoxb8 neutrophil progenitors during their subsequent differentiation (**Fig. 3**). SCF ER-Hoxb8 neutrophil progenitors expressed the stem cell genes *Cd34*, *Flt3*, *Calcr1*, *C1qr1*, *Sox4*, *Hmgn1*, *Hmga2*, *Meis1*, *Erg* and *Nrip1*, which were not expressed in GM-CSF ER-Hoxb8 macrophage progenitors and were shut off during differentiation of SCF ER-Hoxb8 neutrophil progenitors (**Supplementary Table 1**). The more committed differentiation stage of GM-CSF ER-Hoxb8 progenitors was mirrored by their lower expansion potential; inactivation of ER-Hoxb8 in GM-CSF progenitors resulted in cell cycle arrest after only a fourfold expansion, whereas inactivation of ER-Hoxb8 in SCF ER-Hoxb8 neutrophil progenitors was followed by a 90-fold expansion.

Regardless of their striking difference in expansion potential, promyelocytic genes, cell cycle genes and genes encoding cell cycle regulators were downregulated coincident with upregulation of differentiation genes in both progenitor types (**Supplementary**

Fig. 3 online). Cell cycle genes (for example, *Ccnb1* (also known as *CycB1*) and *Mcm2*), as well as Myc target genes (for example, *Nolc1* and *Shmt2*) fell in parallel with expression of *Myc*, *Myb*, *Ruvbl1* and *Ruvbl2*. Expression of the Myb targets, *Ela2*, *Ctsg*, *Prt3* and *Mpo* fell in parallel with *Myb*. Synchronous expression of terminal differentiation genes *Fpr1*, *Fpr-rs2*, *Clec7A*, *Mrc1* and *Fgr* paralleled that of the leucine zipper transcription factor genes *Atf3*, *JunB*, *Fos* and *Jund1*. This suggests that a broad program of cell cycle gene down-regulation and differentiation gene upregulation (**Supplementary Table 2**) is driven by downregulation of *Myc* and *Myb* and upregulation of genes encoding bZIP transcription factors^{10–12}.

Genes controlling divergent aspects of neutrophil and macrophage biology were regulated normally in this cell differentiation model (**Supplementary Tables 1–3**). Maturing phagocytes upregulated genes encoding proteins involved in adhesion (*Itgax*, *Itgam*, *Gpnmb*, *Bst1*), migration (*Cd74*, *Ccr1*, *Ccr5*), phagocytosis (*Sirpb1*, *Clec4b*, *Clec4a3*), activation (*Clec2i*), pathogen pattern recognition (*Mgl2*, *Clec4d*, *Mrc1*, *Clec7a*, *Fpr1*, *Fpr-r2*, *Bst1*), recognition of necrotic cell debris (*Msr1*, *Msr2*, *Cd68*), T-cell activation (*Il18* and genes encoding major histocompatibility complex (MHC) class II antigens *E α* , *A β 1*, *A α* , *E α* , *E β 1*, DM loci α and β 2), MHC class I recognition (*Pira1*, *Pilra*, *Pira6*, *Pilrb1*, *Pirb5*), migration (*Cxcl2*, *Ccr2*), bacterial killing (*Ngp*, *Camp*), opsinophagocytosis (*C3*, *C3ar1*), proteolysis and MHC class II peptide generation (*Lgmn*, *Mmp9*), protease inhibition (*Stfa1*, *Stfa2l1*, *Stfa3*, *Timp2*, *Exp1*), nitric oxide biosynthesis (*Arg2*, *Pdi4*), metal ion transport (*Slc11a1*, *Ltf*) and receptor signaling via tyrosine kinases (*Hck*, *Fgr*).

SCF ER-Hoxb8 progenitors mimic the GMP stem cell

Although expression of promyelocytic genes (for example, *Mpo* and *Prt3*) established SCF ER-Hoxb8 progenitors as myeloid, their expression of multipotent stem cell genes *Flt3*, *CD34*, *Meis1* and *Hmgn1*, coupled with their negligible basal expression of any terminal differentiation gene and their low level of differentiation to mast cells and eosinophils (<2%), suggested they might retain the ability to execute alternative differentiation fates in response to




Figure 5 | Re-expression of TRAF3 restores the signaling defect in CpG-induced transactivation of *Ifn* and *IL-10* genes in *Traf3*^{-/-} macrophages produced by ER-Hoxb8. Wild-type (WT) and *Traf3*^{-/-} ER-Hoxb8-immortalized macrophage progenitor cells (cultured in GM-CSF) were transduced with MSCV-Puro retroviral vectors encoding HA-tagged TRAF3 or a control empty vector and selected with puromycin¹³. (a) TRAF3 expression was measured by intracellular staining with anti-HA antibodies using flow cytometry, and is presented as fluorescence intensity vs. cell number. (b) HA-TRAF3 expression in *Traf3*^{-/-} progenitors transduced with control vector or the HA-TRAF3 expression vector after differentiation for 6 d in the absence of estrogen. Cell lysates were analyzed by immunoblotting, using antibodies to HA and p38. (c) Differentiated ER-Hoxb8 macrophages were stimulated with CpG-DNA and analyzed for interferon and IL-10 production by bioassay and ELISA, respectively. ND, not detectable.

other lineage-specific cytokines. To test this hypothesis, we allowed SCF ER-Hoxb8 progenitors to differentiate in SCF medium supplemented with G-CSF, IL-5, M-CSF, GM-CSF or erythropoietin (Fig. 4). Inclusion of G-CSF augmented chromatin condensation and increased expansion from 70- to 120-fold. Inclusion of IL-5 induced eosinophilic granules in one-third of maturing granulocytes. Inclusion of GM-CSF increased expansion to 830-fold and produced 16% macrophages. Southern blots demonstrated the same unique retroviral integration site in macrophages derived from differentiation in GM-CSF as for neutrophils derived by differentiation in SCF, proving the multipotent nature of this progenitor (data not shown). M-CSF did not alter expansion, but induced 6% of progenitors to mature as macrophages. Erythropoietin had no impact on neutrophil-committed differentiation. Thus, SCF ER-Hoxb8 progenitors are similar to granulocyte-macrophage progenitors (GMP), which retain the ability to differentiate into eosinophils, neutrophils or macrophages.

ER-Hoxb8 macrophages exhibit robust inflammatory responses

We evaluated the inflammatory response of ER-Hoxb8 macrophages by measuring gene activation in response to lipopolysaccharide, an activator of toll-like receptor 4 (TLR4) and bacterial lipoprotein (BLP), an activator of toll-like receptor 2 (TLR2). Lipopolysaccharide activated strong transcription of the genes encoding members of the NF- κ B, Stat, Jun and Egr families of transcription factors (Supplementary Fig. 4 online), as well as over 50 genes encoding mediators of inflammation (Supplementary

Table 4), including coactivators of T-cell migration and proliferation (Tnfs9, Il12b, Il23), monocyte chemokines (Ccl2, Ccl3, Ccl5, Ccl7) and pleiotropic cytokines (Ifnb, Tnfa, IL6, IL1a, IL1b, LIF).

ER-Hoxb8 immortalizes e13 fetal liver progenitors

A useful application of the ER-Hoxb8 system would be to immortalize progenitors from mice carrying transgenic or knockout alleles designed to address immunologic and inflammatory functions, particularly those from mice that are difficult to breed or have poor survival rates. To address this issue, we tested whether macrophages produced by maturation of ER-Hoxb8 GM-CSF progenitors from *Traf3*^{-/-} mice would exhibit a signaling defect that could be corrected by expression of wild-type *Traf3* in *trans*. TRAF3 is essential for induction of type I interferons and the anti-inflammatory cytokine IL-10, but is dispensable for induction of pro-inflammatory cytokines¹³. *Traf3*^{-/-} mice die shortly after birth from hypoglycemia and a runting disease that prevents the generation of substantial numbers of macrophages from *Traf3*^{-/-} mice. We infected *Traf3*^{-/-} e13 fetal liver progenitors with ER-Hoxb8 retrovirus and observed progenitor immortalization. To reconstitute *Traf3*, we expressed hemagglutinin (HA)-tagged *Traf3* by infection with an MSCV-based retroviral vector (Fig. 5a). Expression of the gene encoding HA-TRAF3 persisted in differentiated monocytes produced by estrogen withdrawal (Fig. 5b). We stimulated the differentiated ER-Hoxb8 *Traf3*^{-/-} monocytes and their siblings expressing HA-TRAF3 with CpG-DNA (TLR9 agonist) and measured interferon and IL-10 production by bioassay and enzyme-linked immunosorbent assay (ELISA), respectively. Whereas *Traf3*^{-/-} macrophages produced no interferon or IL-10, we detected robust expression in wild-type cells and in *Traf3*^{-/-} macrophages reconstituted with HA-TRAF3 (Fig. 5c). Thus, ER-Hoxb8-immortalized e13 fetal liver progenitors can be prepared from knockout mice whose lethal genetic phenotype would preclude extensive *ex vivo* studies. Then function encoded by the genetic knockout can be reconstituted in ER-Hoxb8 progenitors, and the abundant source of phagocytes generated by the system provides a convenient means to study functional properties of the knockout protein in mature phagocytes.

DISCUSSION

Here we describe a rapid and convenient method to produce unlimited macrophages or neutrophils from mice surviving past e13, a method that overcomes the considerable time, cost and animal mortality involved in using mice as a source of mature phagocytes. Macrophage differentiation of ER-Hoxb8 GM-CSF progenitors is at least as good as that produced by tetradecanoyl phorbol myristyl acetate (TPA) treatment of HL60 cells, IL6 treatment of M1 acute myelocytic leukemia (AML) cells, or M-CSF treatment of *Hoxa9* progenitors. Although each of these other models of macrophage differentiation is accompanied by upregulation of *Egr1*, *Egr2*, *Atf3*, *Fos*, *Jun* and *RelB* and downregulation of *Myb* and *Myc* transcription¹⁰⁻¹², they also yield heterogeneous morphologies accompanied by considerable apoptosis, likely to be the result of an incomplete differentiation program that is counteracted by the presence of active oncoproteins. The functional maturation of neutrophils derived from ER-Hoxb8 SCF progenitors is stronger than that produced by G-CSF-induced differentiation of either 32D progenitors or *Hoxa9* progenitors. The 32D progenitors fail to upregulate secondary granule genes such as *Ltf*,

and *Hoxa9* progenitors fail to downregulate *Myb* and the promyelocytic genes *Ela2* and *Mpo*, and fail to upregulate the secondary granule gene *Ltf*. The incomplete transcriptional modeling of these inducible cell lines is likely due to the persistent oncoprotein activity during differentiation induction, which contrasts the complete inactivation in oncoprotein-ER fusions. All-*trans* retinoic acid (ATRA)-induced differentiation of GM-CSF-dependent EPRO promyelocytes¹⁴ yields results comparable to those observed with ER-*Hoxb8*, and notably, also inactivates the intrinsic oncoprotein (a dominant-negative retinoic acid receptor α), in the presence of supra-physiologic levels of ATRA.

Other conditional oncoproteins described to date have not evidenced reproducible derivation of lineage-specific progenitors that execute normal differentiation. Avian v-Myb-ER immortalizes primary chicken monocyte progenitors that differentiated, unexpectedly, into multinucleated giant cells similar to bone-marrow-derived osteoclasts¹⁵. Their expansion in the presence of estrogen is also limited to 10^7 cells. Mll-Enl-ER (tamoxifen-regulated) immortalizes a biphenotypic progenitor that requires 14 d to exit the cell cycle after removal of tamoxifen, and to differentiate into neutrophils and monocytes¹⁶. Terminal differentiation of progenitors immortalized by E2a-ER-Pbx1 is variable (5–12 d), and although derivation of neutrophil-committed progenitors is frequently observed using the $\Delta 1$ E2a-Pbx1 mutant, derivation of macrophage-committed progenitors is rare¹⁷, an observation somewhat akin to the behavior of ER-*Hoxa9* in this study, which yielded mostly biphenotypic progenitors, a lower number of neutrophil-committed progenitors and rare monocyte-committed progenitors. Therefore, oncoprotein-specific functions dictate the expansion potential, differentiation stage and differentiation fate of immortalized progenitors. ER-*Hoxb8* has the advantage of targeting or programming progenitors so that its subsequent inactivation results in their predictable differentiation into neutrophils or macrophages.

ER-*Hoxb8* is unique in being able to target two different types of progenitors, one producing macrophages and another producing neutrophils under defined cell-culture conditions. These properties will be useful for investigations into the differentiation, signaling and effector mechanisms of phagocytes, and having an infinite supply of cells will permit functional analysis by classical biochemistry or molecular biology approaches. One clear application of this system is to understand how Hox oncoproteins maintain the undifferentiated state in human myeloid leukemia, a goal that can now be approached by determining the biochemical link between Hox activity and maintaining transcription of other proto-oncogenes involved in cancer and stem cell expansion, such as *Myb*^{18–21}, *Myc*²², *Ruvb1* (ref. 23), *Gfi1* (ref. 24) and *Hmgb3* (ref. 25). A second application is to understand transcriptional mechanisms governing terminal phagocyte differentiation, such as those controlling activation of *Lfn*, the pattern recognition gene *Fpr*, or the antimicrobial gene *Camp*. Studies focused on macrophage differentiation lack easily derived model systems¹⁴. A third application is to identify new genes controlling phagocyte differentiation, an example of which may be 30-fold upregulation of the dual-specificity phosphatase *Dusp1* (cell cycle regulation²⁶) and strong downregulation of the tyrosine phosphatase *Ptpn1*.

The accuracy of ER-*Hoxb8* progenitors in modeling normal differentiation suggests it should be possible to derive hematopoietic progenitors that model erythroid, megakaryocytic or lymphoid

differentiation, or even epithelial progenitors that model breast ductal formation or colonic microvillar differentiation using conditional oncogenes that are native to tumors within these progenitors coupled with cytokines that drive their normal expansion. Such models of tissue differentiation would be useful tools in understanding the biochemistry and genetics of how oncogenes enforce the stem-cell phenotype, as well as in understanding the functions of differentiated cell types that are difficult to culture from native sources.

METHODS

General methods. We performed spectral karyotype analysis²⁷ and northern blots²⁸ as described previously. For western blotting, we used antibodies to *Hoxa9*, Flag, HA, RelB, Jun, RelA and Msr1 as described previously^{6,17,29,30}. FACS analysis, Wright-Giemsa staining, the nitroblue tetrazolium reduction (NBT) assay and the nonspecific esterase (NSE) assay were performed as described previously¹⁷.

Derivation of SCF-dependent neutrophil progenitors using negative selection of progenitors followed by cytokine pre-stimulation and cultivation in SCF. We harvested bone marrow from the femur and tibia of female Balb/c mice and obtained lineage-negative progenitors by negative selection using an antibody cocktail reactive against Mac1, B220 and Thy1.2 followed by removal of lin⁺ cells on a magnetic column (Stemcell Technologies). We pre-stimulated progenitors for 48 h in Iscoves modified Dulbecco medium (IMDM) containing 15% fetal bovine serum (FBS), 1% penicillin-streptomycin-glutamine (PSE; Gibco), 50 ng/ml stem cell factor (SCF), 25 ng/ml IL-3 and 25 ng/ml IL-6. We infected 25,000 marrow progenitors with 1 ml ER-*Hoxb8* retrovirus by spinoculation (2,500g, 2 h, 22 °C) in the presence of lipofectamine (1:1,000; Gibco), as described in **Supplementary Methods**. We culture the infected progenitors in OptiMem medium containing 10% FBS, 1% PSE, 10 ng/ml SCF, 30 μ M β -mercaptoethanol (1 μ l into 500 ml medium), and 1 μ M β -estradiol (estrogen; Sigma). We approximated an infection efficiency of 10% based on comparison of the initial rates of progenitor outgrowth in the presence or absence of G418 selection. We enriched immortalized myeloid progenitors by the serial passage of nonadherent cells every 3 d into new 12-well tissue culture plates. Immortalized progenitors predominated cultures infected by Hox-ER retroviruses by day 14 (cell generation time 18–20 h), whereas control cultures had reduced proliferation and stopped dividing by day 21. If GM-CSF was substituted for SCF during selection of immortalized progenitors in this protocol, clones yielding biphenotypic differentiation to neutrophils and macrophages arose. A detailed protocol is available in **Supplementary Methods**.

Derivation of macrophage-committed progenitors immortalized by ER-*Hoxb8* or of biphenotypic, neutrophil or macrophage progenitors immortalized by *Hoxa9*-ER. We isolated bone marrow from the femurs of mice after ammonium sulfate lysis of red blood cells and centrifugation onto a cushion of Ficoll-Paque (Pharmacia). Ficoll-purified progenitors can be used directly or pre-stimulated 48 h in 50 ng/ml SCF, 25 ng/ml IL3 and 25 ng/ml IL6. We subjected 100,000 Ficoll-purified mononuclear cells to spinoculation with 1 ml of ER-*Hoxb8* retrovirus. We cultured infected progenitors in 'myeloid cell medium' (RPMI 1640 with

10% FBS, 1% PSQ, 1% GM-CSF–conditioned medium from B16 melanoma expressing the *Csf2* cDNA (approximately 10 ng/ml GM-CSF) and 1 μ M estrogen). We stored estrogen as 1,000 \times (1 mM) or 10,000 \times (10 mM) stocks in 100% ethanol at -20°C . We approximated an infection efficiency of 10% based on comparison of rates of progenitor outgrowth in the presence of G418, which selects for the coexpressed neomycin phosphotransferase gene encoded by MSCV. We selected immortalized myeloid progenitors by removal of nonadherent progenitor cells every 3 d to a new well in a six-well culture plate. We continued this procedure over 3 weeks to produce immortalized macrophage progenitor lines. Selection for G418 resistance permitted derivation of immortalized progenitors in 10–14 d. Differentiation to macrophages was performed in the same base medium. Detailed protocols are available in **Supplementary Methods**.

Derivation of neutrophil, macrophage and biphenotypic progenitors, using ER-Hoxa9 or Hoxa7. These progenitors were derived using the same culture system as described for GM-CSF ER-Hoxb8 macrophage progenitors. Derivation of progenitors committed exclusively to neutrophil or monocyte differentiation required cloning, which we performed using 96-well microtiter plates.

Institutional committee approval for animal use. Experimental protocols were approved by the University of California, San Diego animal subjects committee.

Additional methods. contains experimental details on construction of ER-Hox proteins, cell culture and freezing techniques, luciferase reporter assays, Affymetrix array analysis, and in-depth descriptions of the derivation of GM-CSF ER-Hoxb8 and SCF ER-Hoxb8 progenitor lines are available in **Supplementary Methods**.

Note: Supplementary information is available on the Nature Methods website.

ACKNOWLEDGMENTS

This work is supported by Public Health Service grant (National Institutes of Health CA56876) awarded to M.P.K. We thank D. Young for assistance with FACS analysis, and G. Chun and W. Westra at Scripps Research Foundation for collaborating in the spectral karyotype analysis.

COMPETING INTERESTS STATEMENT

The authors declare competing financial interests (see the *Nature Methods* website for details).

Published online at <http://www.nature.com/naturemethods/>

Reprints and permissions information is available online at

<http://ngp.nature.com/reprintsandpermissions/>

- Karin, M. & Greten, F.R. NF- κ B: linking inflammation and immunity to cancer development and progression. *Nat. Rev. Immunol.* **5**, 749–759 (2005).
- Weisberg, S.P. *et al.* Obesity is associated with macrophage accumulation in adipose tissue. *J. Clin. Invest.* **112**, 1796–1808 (2003).
- Pineault, N., Helgason, C.D., Lawrence, H.J. & Humphries, R.K. Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny. *Exp. Hematol.* **30**, 49–57 (2002).
- Lawrence, H.J. *et al.* Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. *Blood* **89**, 1922–1930 (1997).
- Thorsteinsdottir, U. *et al.* Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. *Blood* **99**, 121–129 (2002).
- Calvo, K.R., Sykes, D.B., Pasillas, M. & Kamps, M.P. Hoxa9 immortalizes a granulocyte-macrophage colony-stimulating factor-dependent promyelocyte capable of biphenotypic differentiation to neutrophils or macrophages, independent of enforced meis expression. *Mol. Cell. Biol.* **20**, 3274–3285 (2000).
- Knoepfler, P.S., Sykes, D.B., Pasillas, M. & Kamps, M.P. HoxB8 requires its Pbx-interaction motif to block differentiation of primary myeloid progenitors and of most cell line models of myeloid differentiation. *Oncogene* **20**, 5440–5448 (2001).
- Fischbach, N.A. *et al.* HOXB6 overexpression in murine bone marrow immortalizes a myelomonocytic precursor *in vitro* and causes hematopoietic stem cell expansion and acute myeloid leukemia *in vivo*. *Blood* **105**, 1456–1466 (2005).
- Owens, B.M. & Hawley, R.G. HOX and non-HOX homeobox genes in leukemic hematopoiesis. *Stem Cells* **20**, 364–379 (2002).
- Krishnaraju, K., Hoffman, B. & Liebermann, D.A. The zinc finger transcription factor Egr-1 activates macrophage differentiation in M1 myeloblastic leukemia cells. *Blood* **92**, 1957–1966 (1998).
- Liebermann, D.A. & Hoffman, B. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation. *Stem Cells* **12**, 352–369 (1994).
- Kharbanda, S. *et al.* Expression of the early growth response 1 and 2 zinc finger genes during induction of monocytic differentiation. *J. Clin. Invest.* **88**, 571–577 (1991).
- Hacker, H. *et al.* Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. *Nature* **439**, 204–207 (2006).
- Gaines, P., Chi, J. & Berliner, N. Heterogeneity of functional responses in differentiated myeloid cell lines reveals EPRO cells as a valid model of murine neutrophil functional activation. *J. Leukoc. Biol.* **77**, 669–679 (2005).
- Engelke, U., Wang, D.M. & Lipsick, J.S. Cells transformed by a v-Myb-estrogen receptor fusion differentiate into multinucleated giant cells. *J. Virol.* **71**, 3760–3766 (1997).
- Zeisig, B.B. *et al.* Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. *Mol. Cell. Biol.* **24**, 617–628 (2004).
- Sykes, D.B. & Kamps, M.P. Estrogen-dependent E2a/Pbx1 myeloid cell lines exhibit conditional differentiation that can be arrested by other leukemic oncoproteins. *Blood* **98**, 2308–2318 (2001).
- Lipsick, J.S. & Wang, D.M. Transformation by v-Myb. *Oncogene* **18**, 3047–3055 (1999).
- Chen, J., Kremer, C.S. & Bender, T.P. A Myb dependent pathway maintains Friend murine erythroleukemia cells in an immature and proliferating state. *Oncogene* **21**, 1859–1869 (2002).
- Lyon, J.J. & Watson, R.J. Conditional inhibition of erythroid differentiation by c-Myb/oestrogen receptor fusion proteins. *Differentiation* **59**, 171–178 (1995).
- White, J.R. & Weston, K. Myb is required for self-renewal in a model system of early hematopoiesis. *Oncogene* **19**, 1196–1205 (2000).
- Kumar, A., Lee, C.M. & Reddy, E.P. c-Myc is essential but not sufficient for c-Myb-mediated block of granulocytic differentiation. *J. Biol. Chem.* **278**, 11480–11488 (2003).
- Wood, M.A., McMahon, S.B. & Cole, M.D. An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc. *Mol. Cell* **5**, 321–330 (2000).
- Hock, H. *et al.* Intrinsic requirement for zinc finger transcription factor Gfi-1 in neutrophil differentiation. *Immunity* **18**, 109–120 (2003).
- Nemeth, M.J., Cline, A.P., Anderson, S.M., Garrett-Beal, L.J. & Bodine, D.M. Hmgb3 deficiency deregulates proliferation and differentiation of common lymphoid and myeloid progenitors. *Blood* **105**, 627–634 (2005).
- Li, M., Zhou, J.Y., Ge, Y., Matherly, L.H. & Wu, G.S. The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. *J. Biol. Chem.* **278**, 41059–41068 (2003).
- Yang, A.H. *et al.* Chromosome segregation defects contribute to aneuploidy in normal neural progenitor cells. *J. Neurosci.* **23**, 10454–10462 (2003).
- Sykes, D.B. & Kamps, M.P. Estrogen-regulated conditional oncoproteins: tools to address open questions in normal myeloid cell function, normal myeloid differentiation, and the genetic basis of differentiation arrest in myeloid leukemia. *Leuk. Lymphoma* **44**, 1131–1139 (2003).
- Wang, G.G., Pasillas, M.P. & Kamps, M.P. Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with PBX and a novel function of the Meis1 C terminus. *Blood* **106**, 254–264 (2005).
- Park, J.M. *et al.* Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis-CREB and NF- κ B as key regulators. *Immunity* **23**, 319–329 (2005).